https://www.thebodypro.com/category/hiv-treatments-in-development
HIV Treatment Strategies

HIV Treatments in Development

The Latest

Monkeys Suppress HIV-Like Virus for Extended Period After Dual-Antibody Treatment Img

Monkeys Suppress HIV-Like Virus for Extended Period After Dual-Antibody Treatment

Giving monkeys two powerful anti-HIV antibodies immediately after infection with an HIV-like virus enabled the immune systems of some of the animals to control the virus long after the antibodies were gone.

3 Broadly Neutralizing Antibodies May Explain How Individual Controls HIV Without Treatment Img

3 Broadly Neutralizing Antibodies May Explain How Individual Controls HIV Without Treatment

Three broadly neutralizing antibodies in an HIV-positive person may explain how this individual controlled HIV for 30 years without antiretroviral therapy.

New HIV Capsid Inhibitor Strongly Stops HIV Replication at Two Steps Img
CROI (Conference on Retroviruses and Opportunistic Infections)

New HIV Capsid Inhibitor Strongly Stops HIV Replication at Two Steps

A first-in-class HIV-1 capsid inhibitor interrupts replication at two steps of the viral lifecycle and has pharmacokinetic properties that may permit once-monthly or less frequent dosing.

Antibody Therapies Effective at Preventing HIV From Invading CD4 Cells Img
CROI (Conference on Retroviruses and Opportunistic Infections)

Antibody Therapies Effective at Preventing HIV From Invading CD4 Cells

Two new monoclonal antibodies demonstrated success in helping people living with HIV suppress their viral loads to undetectable levels.

Pregnancy Common in ART Trials in Sub-Saharan Africa Despite Exclusion Criteria Img

Pregnancy Common in ART Trials in Sub-Saharan Africa Despite Exclusion Criteria

A new analysis reports that HIV-positive women in clinical trials in sub-Saharan Africa are likely to get pregnant as often as those receiving care outside of research settings.

HIV Vaccine Induces Sustained HIV Remission in Proof-of-Concept Study Img
CROI (Conference on Retroviruses and Opportunistic Infections)

HIV Vaccine Induces Sustained HIV Remission in Proof-of-Concept Study

Two doses of a therapeutic HIV vaccine plus three infusions of romidepsin, an HIV latency reactivator, allowed five of 13 trial participants to stay off antiretroviral therapy without rebound for up to 28 weeks in a Spanish proof-of-concept study....

Paul Sax, M.D.
CROI (Conference on Retroviruses and Opportunistic Infections)

Top HIV Researcher Hails a Resurgent Antiretroviral Pipeline

Paul Sax, M.D., discusses the clinical importance of new drugs in development highlighted at CROI 2017 -- and about what else is on the near horizon when it comes to antiretroviral therapies for HIV.

NRTI GS-9131 Resurfaces at CROI 2017: In Vitro Sensitivity to Nuke-Resistant HIV Img
CROI (Conference on Retroviruses and Opportunistic Infections)

NRTI GS-9131 Resurfaces at CROI 2017: In Vitro Sensitivity to Nuke-Resistant HIV

A CROI 2017 poster presented in vitro results of an NRTI compound from Gilead that appears has been in preclinical development for at least a decade.

NIH Research Helps Explain How Antibody Treatment Led to Sustained Remission of HIV-Like Virus Img
CROI (Conference on Retroviruses and Opportunistic Infections)

NIH Research Helps Explain How Antibody Treatment Led to Sustained Remission of HIV-Like Virus

NIH scientists have found that the presence of the protein alpha-4 beta-7 integrin on the surface of HIV and SIV may help explain why an antibody protected monkeys from SIV in previous experiments.

Pharmacokinetics and Full Phase 2 Results for Bictegravir, a New Integrase Inhibitor Img
CROI (Conference on Retroviruses and Opportunistic Infections)

Pharmacokinetics and Full Phase 2 Results for Bictegravir, a New Integrase Inhibitor

Two oral presentations on a new integrase inhibitor bictegravir were included in the first session at CROI 2017 looking at new treatment and treatment strategies.